The Use of rhBMP-2 in Interbody Fusion Cages: Definitive Evidence of Osteoinduction in Humans: A Preliminary Report

By S. Boden, T. Zdeblick, H. Sandhu, S. Heim. Spine, 2000

714 citations recorded by the source corpus.

Subfields: Pathology and Forensic Medicine, Surgery

View Paper: https://www.semanticscholar.org/paper/f5e80b4b2c4789b70f5f2e528b7a8bcde74b7af1

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Pathology and Forensic Medicine

1. E. Carragee
2. E. Hurwitz
3. Bradley Weiner

In Surgery

1. E. Carragee
2. E. Hurwitz
3. Bradley Weiner

Citations in the corpus

• A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned. (2011, methodology): “Six-week postoperative data of early evidence of possible increased functional impairment and radiculitis after posterolateral fusion with recombinant human bone morphogenetic protein-2 (rhBMP-2) compared with control patients [2].”
• Anterior Lumbar Interbody Fusion Using rhBMP-2 With Tapered Interbody Cages (2002, background): “Recently, cylindrical threaded intervertebral devices with autogenous bone grafts have been shown to stabilize a lumbar motion segment after anterior discectomy, and their use has led to high rates of fusion and improved clinical outcomes (12).”
• Adverse Effects Associated With High-Dose Recombinant Human Bone Morphogenetic Protein-2 Use in Anterior Cervical Spine Fusion (2006, background): “The morbidity resulting from graft-site harvest may affect up to 30% of patients, and include neurologic damage, chronic pain, and risk of infection.(1,2) This staggering percentage led to the use of bone graft substitutes, including homologous bone and a family of growth factors known as bone morph”
• Recombinant Human Bone Morphogenetic Protein-2 for Treatment of Open Tibial Fractures: A Prospective, Controlled, Randomized Study of Four Hundred and Fifty Patients (2002, neutral): “Final study visit not completed* 12 (8) 9 (6) 8 (5) 29 (6)”
• Collagen sponges for bone regeneration with rhBMP-2. (2003, background): “[22] determined that rhBMP-2/ACS-filled interbody fusion cages were more successful in achieving arthrodesis in patients compared to autograft with no adverse events.”
• Osteoinductive ceramics as a synthetic alternative to autologous bone grafting (2010, background): “The latter treatment is a commercially available product used for spinal fusion surgery (23, 24).”
• Use of Recombinant Human Bone Morphogenetic Protein-2 to Achieve Posterolateral Lumbar Spine Fusion in Humans: A Prospective, Randomized Clinical Pilot Trial 2002 Volvo Award in Clinical Studies (2002, background): “Since bone induction by BMP-2 occurs well before 12 months, previous clinical studies of rhBMP-2 in anterior lumbar interbody arthrodesis have shown that the radiographic outcome is measurable by 6 months and does not change at 12 or 24 months.(13) We are not certain whether the results in the autog”